Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: A16AX

Cuprior(trientine tetrahydrochloride)

Hepatolenticular Degeneration

Marketing Authorisation Holder: Orphalan

EMA Authorisation: 05/09/2017

INN: trientine

Indication

Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Cuprior — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.